Thiogenesis to Present Clinical Updates in MELAS and Leigh Syndrome Spectrum at UMDF Bench-to-Bedside Webinar
San Diego, California–(Newsfile Corp. – January 5, 2026) – Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) (“Thiogenesis” or the “Company”), a clinical-stage biotechnology company developing next-generation sulfur-based prodrugs for rare mitochondrial and metabolic diseases, today announced that its Chief Executive Officer, Patrice Rioux, MD, Ph.D., will participate as a panelist in the United Mitochondrial Disease […]